PTC Therapeutics is committed to the Duchenne and Becker community and we take very seriously our responsibility to the patients and families whose participation in our trials is so crucial to the development of ataluren. Since we regained the worldwide rights to ataluren, we have been working very actively to initiate a study that will be open to all patients, regardless of ambulation status, who received ataluren in a prior PTC-sponsored DBMD study in Europe, Israel or Australia.

This clinical study will have an open-label design, similar to the ongoing clinical trial in the US for previous ataluren trial patients. As with the original Phase 2b study, the start date for each site will be influenced by factors including the national regulatory and local ethics committee approval processes and the need in most cases to translate trial documents. Our goal is to have the protocol submitted to sites and regulatory authorities by the end of December. We have hired a contract research organization, as we did for the Phase 2b and for the US open-label safety study, to manage this new study on our behalf. You will be contacted by your principal investigator or a member of his or her staff as soon as your site is ready to begin enrollment.